In a report published Tuesday, Oppenheimer analyst Steven Lichtman initiated coverage on InspireMD NSPR with an Outperform rating and $6.00 price target.
In the report, Oppenheimer noted, “We are initiating coverage of InspireMD, Inc. with an Outperform rating and $6 price target. We view InspireMD's proprietary, CE Mark approved MGuard Embolic Protection Stent (EPS) as a novel and potentially disruptive technology for the treatment of ST Elevation Myocardial Infarction (severe heart attacks, or STEMI). MGuard's US pivotal trial is currently enrolling and we anticipate FDA approval in late 2016. In the interim, we look for recently presented positive 12-month follow-up data from the randomized MASTER trial to drive meaningful sales growth internationally. Key pipeline opportunities such as MGuard Carotid and drug-eluting MGuard represent potential upside to our model.”
InspireMD closed on Monday at $2.55.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in